eClinical Technology and Industy News

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients –

– CDK9 inhibitor PRT2527 demonstrates strong efficacy in hematological malignancies and solid tumor models with MYC dysregulation in preclinical studies –

Excerpt from the Press Release:

WILMINGTON, Del., Oct. 07, 2021 (GLOBE NEWSWIRE) — Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of data from multiple pipeline programs, including the dose escalation portions of the Company’s ongoing Phase 1 trials of lead oral protein arginine methyltransferase 5 (PRMT5) inhibitors PRT543 and PRT811. These data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

“We are encouraged by the Phase 1 dose escalation data for our lead oral PRMT5 inhibitors, PRT543 and PRT811, both of which demonstrated favorable safety profiles, dose-dependent increases in pharmacokinetic parameters, target engagement, and achieved degrees of PRMT5 inhibition required for efficacy in preclinical models at well tolerated doses. We are also encouraged by the preliminary clinical activity observed with both molecules in multiple tumor types, including durable responses in cancers with high unmet need. Importantly, our brain penetrant molecule, PRT811, demonstrated a very high level of systemic PRMT5 inhibition at well tolerated doses and without central nervous system adverse events, which expands the potential clinical utility of this molecule,” said Kris Vaddi, Ph.D., Chief Executive Officer. “We are leveraging insights from these data as we move forward through the expansion cohorts in selected patient populations, and we anticipate a cadence of data from these cohorts throughout 2022.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?